If you have been reading about reversed-phase HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Approximate, for sequence GEPPPGKPADDAGLV |
| Molecular mass | ~1419 Da | Neutral form |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also soluble in aqueous buffers |
| Typical storage | -20 C | Dry powder, protected from moisture |
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
=== Symptoms and treatment === The diagnosis of pufferfish poisoning is based on the observed symptomatology and recent dietary history. Symptoms typically develop within 30 minutes of ingestion, but may be delayed by up to four hours; however, if the dose is fatal, symptoms are usually present within 17 minutes of ingestion. Having pins and needles of the lips and tongue is followed by developing it in the extremities, hypersalivation, sweating, headache, weakness, lethargy, incoordination, tremor, paralysis, bluish skin, loss of voice, difficulty swallowing, and seizures. The gastrointestinal symptoms are often severe and include nausea, vomiting, diarrhoea, and abdominal pain; death is usually secondary to respiratory failure. There is increasing respiratory distress, speech is affected, and the victim usually exhibits shortness of breath, excess pupil dilation, and abnormally low blood pressure. Paralysis increases, and convulsions, mental impairment, and irregular heartbeats may occur. The victim, although completely paralysed, may be conscious and in some cases completely lucid until shortly before death, which generally occurs within 4 to 6 hours (range ~20 minutes to ~8 hours). However, some victims enter a coma.
=== 19 May === The SAF retook Wadi al-Atrun in Al-Malha, located on a strategic road linking Northern State and North Darfur. The SAF also retook Al-Salha in Omdurman, Al Alqa in the White Nile, and the Um Libana area in West Kordofan. General al-Burhan appointed Kamil Idris as prime minister.
The Clinical Hemostasis Handbook. Chicago: Year Book Medical Publishers. Laposata, M. (2010–2013). Coagulation Disorders. Quality in Laboratory Diagnosis series. New York: Demos Medical Publishing. Laposata was also editor of the full six-volume series (Laboratory Management, Clinical Microbiology, Transfusion Medicine, Clinical Chemistry, Hematology/Clinical Immunology, and Coagulation Disorders). Laposata, M. (2016). Clinical Diagnostic Tests: How to Avoid Errors in Ordering Tests and Interpreting Results. New York: Demos Medical Publishing. Laposata, M.; McCaffrey, P. (2022). Clinical Laboratory Methods: Atlas of Commonly Performed Tests and Molecular Test Methods. New York: McGraw-Hill. Laposata, M., ed. (2025). Laposata's Laboratory Medicine: The Diagnosis of Disease in the Clinical Laboratory (4th ed.). Lange Series. New York: McGraw-Hill. Laposata, M.; Dighe, A. S. (2007). "'Pre-pre' and 'post-post' analytical error: High-incidence patient safety hazards involving the clinical laboratory." Clinical Chemistry and Laboratory Medicine. 45: 712–719. Laposata, M. (2014). "Putting the patient first: Using the expertise of laboratory professionals to produce rapid and accurate diagnoses." Laboratory Medicine. 45: 4–5. Graber, M. L.; Rusz, D.; Jones, M. L.; Farm-Franks, D.; Jones, B.; Cyr Gluck, J.; Thomas, D. B.; Gleason, K.; Welte, K.; Abfalter, J.; Westerhaus, K.; Adams, G.; Laposata, M.; Eichbaum, Q.; Nabatchi, T.; Compton, M. (2017). "The new diagnostic team." Diagnosis. 4: 225–238.
== Definition == RiPPs consist of any peptides (i.e. molecular weight below 10 kDa) that are ribosomally-produced and undergo some degree of enzymatic post-translational modification. This combination of peptide translation and modification is referred to as "post-ribosomal peptide synthesis" (PRPS) in analogy with nonribosomal peptide synthesis (NRPS). Historically, the current sub-classes of RiPPs were studied individually, and common practices in nomenclature varied accordingly in the literature. More recently, with the advent of broad genome sequencing, it has been realized that these natural products share a common biosynthetic origin. In 2013, a set of uniform nomenclature guidelines were agreed upon and published by a large group of researchers in the field. Prior to this report, RiPPs were referred to by a variety of designations, including post-ribosomal peptides, ribosomal natural products, and ribosomal peptides. The acronym "RiPP" stands for "ribosomally synthesized and post-translationally modified peptide".
== History == Orexigen Therapeutics submitted a New Drug Application (NDA) for the combination to the FDA in March 2010. Having paid a fee under the Prescription Drug User Fee Act, Orexigen was given a deadline for the FDA to approve or reject the drug of January 2011. In December 2010, an FDA Advisory Committee voted 13–7 to approve Contrave and 11–8 to conduct a post-marketing cardiovascular outcomes study. Subsequently, on 2 February 2011, the FDA rejected the drug, and it was decided that an extremely large-scale study of the long-term cardiovascular effects of Contrave would be needed before approval could be considered. It was ultimately approved in the United States in 2014. In December 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency endorsed the combination for licensure as an obesity medication when used alongside diet and exercise. Authorization was granted in March 2015. A review of Mysimba was completed by the CHMP in March 2025. In May 2015, Orexigen prematurely ended the trial that was intended to test whether naltrexone/bupropion increased the risk of major adverse cardiovascular events in obese patients with cardiovascular disease because an independent panel of experts said that the drug maker "inappropriately" compromised the trial by prematurely releasing interim data. The early data release reported a reduction in heart attacks, but that advantage was no longer observed when a more complete view of the data was analyzed.
Sources: en.wikipedia.org
Estrogen promotes cellular development and prevents programmed cell death (apoptosis) via activating specific pathways mediated by estrogen receptors (ER) in various types of cells. Estrogen promotes the development of breast cancers that have estrogen receptor (ER) by stimulating the proliferation and survival of breast cancer cells. Estrogen receptor (ER) is a significant indicator for predicting outcomes and guiding treatment decisions, and it is found in around 75% of breast cancers. Estrogen triggers apoptosis in breast cancer cells as well as other types of cells. Receptor levels rise as individuals age among certain ethnic groups, and typically, white women have greater receptor levels compared to black or Japanese women. It has been hypothesized that the absence of a tumor-suppressor gene may lead to the inability to decrease the activity of estrogen receptors when cells enter the cell cycle or the inability to inhibit the division of cells that have estrogen receptors. This might potentially be a mechanism for the development of breast cancer.
If anti-TPO is not positive, treatment for subclinical hypothyroidism is not currently recommended. It has been suggested that many of the aforementioned recommendations could lead to unnecessary treatment, in the sense that the TSH cutoff levels may be too restrictive in some ethnic groups; there may be little benefit from treatment of subclinical hypothyroidism in certain cases. Treatment for subclinical hypothyroidism in pregnancy is not conclusively shown to decrease the incidence of miscarriage.
Hypersensitivity to buserelin or any of the other components of the medication (case reports of anaphylaxis exist) Prostate cancer that is not hormone-dependent (as there will be no benefit from testosterone suppression) Individuals who have undergone gonadectomy (as hormone levels will not be affected) Pregnancy and breastfeeding (unknown whether buserelin might be teratogenic) Undiagnosed abnormal vaginal bleeding
== External links == "Stimulant Potentially Dangerous to Health, FDA Warns". U.S. Food and Drug Administration. April 11, 2013. Archived from the original on April 13, 2013. Bussel II, Pavlov Jr AA (June 7, 2013). "DMAA: Efficacious but is it Safe?". Science-Based Medicine. Science Based Medicine Blog.
Sources: en.wikipedia.org
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.
No. The gastric protein is larger, while BPC-157 is a short fragment sequence. The peptide is produced synthetically for research use. The relationship is one of sequence origin, not chemical identity.
It is most often supplied as a lyophilized powder, frequently as the acetate salt. The powder is reconstituted with water or a buffer before use. Free-base and other salt forms also exist but are less common in catalogs.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.